{"filing":{"accession_number":"0001628280-26-051251","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-29","primary_document":"vtgn-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/vtgn-20260729.htm"},"events":[{"id":22886,"run_id":20722,"accession_number":"0001628280-26-051251","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Douglas J. Williamson, M.D. was appointed as a director to Vistagen's Board of Directors, effective July 29, 2026. Dr. Williamson brings nearly three decades of neuroscience drug development and regulatory expertise, including prior roles as Chief Medical Officer and executive positions at major pharmaceutical firms, strengthening the board's clinical and development capabilities.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22978,"accession_number":"0001628280-26-051251","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Douglas J. Williamson, M.D. as a director to the Board of Directors, approved by the Board on July 29, 2026. While the disclosure also includes compensatory details (stock options and director compensation plan eligibility), the principal disclosed action is the appointment itself. Dr. Williamson's extensive neuroscience drug development and regulatory expertise is material to a late-stage biopharmaceutical company advancing its clinical pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:37:26.460274+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22979,"accession_number":"0001628280-26-051251","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Douglas J. Williamson to Vistagen's Board of Directors. The press release emphasizes his extensive neuroscience drug development expertise and leadership experience spanning nearly three decades, including prior roles as Chief Medical Officer at multiple companies and executive positions at major pharmaceutical firms. This is a material governance event affecting board composition at a late-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:37:26.460274+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22978,"accession_number":"0001628280-26-051251","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Douglas J. Williamson, M.D. as a director to the Board of Directors, approved by the Board on July 29, 2026. While the disclosure also includes compensatory details (stock options and director compensation plan eligibility), the principal disclosed action is the appointment itself. Dr. Williamson's extensive neuroscience drug development and regulatory expertise is material to a late-stage biopharmaceutical company advancing its clinical pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:37:26.460274+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-07-31"},{"id":22979,"accession_number":"0001628280-26-051251","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Douglas J. Williamson to Vistagen's Board of Directors. The press release emphasizes his extensive neuroscience drug development expertise and leadership experience spanning nearly three decades, including prior roles as Chief Medical Officer at multiple companies and executive positions at major pharmaceutical firms. This is a material governance event affecting board composition at a late-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:37:26.460274+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-07-31"}]}